The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Deferasirox-Global Market Insights and Sales Trends 2025
Synopsis
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
The global Deferasirox market size is expected to reach US$ 3728.5 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Deferasirox in various end use industries. The expanding demands from the Transfusional Iron Overload and NTDT Caused Iron Overload, are propelling Deferasirox market. 500 mg/Tablet, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 250 mg/Tablet segment is estimated at % CAGR for the next seven-year period.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Deferasirox, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Deferasirox market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Deferasirox market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Deferasirox sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Deferasirox covered in this report include Novartis, Cipla, Natco Pharma and Sun Pharma, etc.
The global Deferasirox market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Cipla
Natco Pharma
Sun Pharma
Global Deferasirox market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Deferasirox market, Segment by Type:
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Global Deferasirox market, by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Deferasirox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
The global Deferasirox market size is expected to reach US$ 3728.5 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Deferasirox in various end use industries. The expanding demands from the Transfusional Iron Overload and NTDT Caused Iron Overload, are propelling Deferasirox market. 500 mg/Tablet, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 250 mg/Tablet segment is estimated at % CAGR for the next seven-year period.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Deferasirox, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Deferasirox market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Deferasirox market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Deferasirox sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Deferasirox covered in this report include Novartis, Cipla, Natco Pharma and Sun Pharma, etc.
The global Deferasirox market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Cipla
Natco Pharma
Sun Pharma
Global Deferasirox market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Deferasirox market, Segment by Type:
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Global Deferasirox market, by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Deferasirox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Deferasirox Market Overview
1.1 Deferasirox Product Overview
1.2 Deferasirox Market Segment by Type
1.2.1 500 mg/Tablet
1.2.2 250 mg/Tablet
1.2.3 125 mg/Tablet
1.2.4 Others
1.3 Global Deferasirox Market Size by Type
1.3.1 Global Deferasirox Market Size Overview by Type (2018-2029)
1.3.2 Global Deferasirox Historic Market Size Review by Type (2018-2023)
1.3.3 Global Deferasirox Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Deferasirox Sales Breakdown by Type (2018-2023)
1.4.2 Europe Deferasirox Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Deferasirox Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Deferasirox Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Deferasirox Sales Breakdown by Type (2018-2023)
2 Global Deferasirox Market Competition by Company
2.1 Global Top Players by Deferasirox Sales (2018-2023)
2.2 Global Top Players by Deferasirox Revenue (2018-2023)
2.3 Global Top Players by Deferasirox Price (2018-2023)
2.4 Global Top Manufacturers Deferasirox Manufacturing Base Distribution, Sales Area, Product Type
2.5 Deferasirox Market Competitive Situation and Trends
2.5.1 Deferasirox Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Deferasirox Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Deferasirox as of 2022)
2.7 Date of Key Manufacturers Enter into Deferasirox Market
2.8 Key Manufacturers Deferasirox Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Deferasirox Status and Outlook by Region
3.1 Global Deferasirox Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Deferasirox Historic Market Size by Region
3.2.1 Global Deferasirox Sales in Volume by Region (2018-2023)
3.2.2 Global Deferasirox Sales in Value by Region (2018-2023)
3.2.3 Global Deferasirox Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Deferasirox Forecasted Market Size by Region
3.3.1 Global Deferasirox Sales in Volume by Region (2024-2029)
3.3.2 Global Deferasirox Sales in Value by Region (2024-2029)
3.3.3 Global Deferasirox Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Deferasirox by Application
4.1 Deferasirox Market Segment by Application
4.1.1 Transfusional Iron Overload
4.1.2 NTDT Caused Iron Overload
4.2 Global Deferasirox Market Size by Application
4.2.1 Global Deferasirox Market Size Overview by Application (2018-2029)
4.2.2 Global Deferasirox Historic Market Size Review by Application (2018-2023)
4.2.3 Global Deferasirox Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Deferasirox Sales Breakdown by Application (2018-2023)
4.3.2 Europe Deferasirox Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Deferasirox Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Deferasirox Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Deferasirox Sales Breakdown by Application (2018-2023)
5 North America Deferasirox by Country
5.1 North America Deferasirox Historic Market Size by Country
5.1.1 North America Deferasirox Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Deferasirox Sales in Volume by Country (2018-2023)
5.1.3 North America Deferasirox Sales in Value by Country (2018-2023)
5.2 North America Deferasirox Forecasted Market Size by Country
5.2.1 North America Deferasirox Sales in Volume by Country (2024-2029)
5.2.2 North America Deferasirox Sales in Value by Country (2024-2029)
6 Europe Deferasirox by Country
6.1 Europe Deferasirox Historic Market Size by Country
6.1.1 Europe Deferasirox Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Deferasirox Sales in Volume by Country (2018-2023)
6.1.3 Europe Deferasirox Sales in Value by Country (2018-2023)
6.2 Europe Deferasirox Forecasted Market Size by Country
6.2.1 Europe Deferasirox Sales in Volume by Country (2024-2029)
6.2.2 Europe Deferasirox Sales in Value by Country (2024-2029)
7 Asia-Pacific Deferasirox by Region
7.1 Asia-Pacific Deferasirox Historic Market Size by Region
7.1.1 Asia-Pacific Deferasirox Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Deferasirox Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Deferasirox Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Deferasirox Forecasted Market Size by Region
7.2.1 Asia-Pacific Deferasirox Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Deferasirox Sales in Value by Region (2024-2029)
8 Latin America Deferasirox by Country
8.1 Latin America Deferasirox Historic Market Size by Country
8.1.1 Latin America Deferasirox Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Deferasirox Sales in Volume by Country (2018-2023)
8.1.3 Latin America Deferasirox Sales in Value by Country (2018-2023)
8.2 Latin America Deferasirox Forecasted Market Size by Country
8.2.1 Latin America Deferasirox Sales in Volume by Country (2024-2029)
8.2.2 Latin America Deferasirox Sales in Value by Country (2024-2029)
9 Middle East and Africa Deferasirox by Country
9.1 Middle East and Africa Deferasirox Historic Market Size by Country
9.1.1 Middle East and Africa Deferasirox Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Deferasirox Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Deferasirox Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Deferasirox Forecasted Market Size by Country
9.2.1 Middle East and Africa Deferasirox Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Deferasirox Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Deferasirox Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Deferasirox Products Offered
10.1.5 Novartis Recent Development
10.2 Cipla
10.2.1 Cipla Company Information
10.2.2 Cipla Introduction and Business Overview
10.2.3 Cipla Deferasirox Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Cipla Deferasirox Products Offered
10.2.5 Cipla Recent Development
10.3 Natco Pharma
10.3.1 Natco Pharma Company Information
10.3.2 Natco Pharma Introduction and Business Overview
10.3.3 Natco Pharma Deferasirox Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Natco Pharma Deferasirox Products Offered
10.3.5 Natco Pharma Recent Development
10.4 Sun Pharma
10.4.1 Sun Pharma Company Information
10.4.2 Sun Pharma Introduction and Business Overview
10.4.3 Sun Pharma Deferasirox Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Sun Pharma Deferasirox Products Offered
10.4.5 Sun Pharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Deferasirox Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Deferasirox Industrial Chain Analysis
11.4 Deferasirox Market Dynamics
11.4.1 Deferasirox Industry Trends
11.4.2 Deferasirox Market Drivers
11.4.3 Deferasirox Market Challenges
11.4.4 Deferasirox Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Deferasirox Distributors
12.3 Deferasirox Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
